Navigation Links
Unilife COO to Again Purchase More Than $250,000 in Company Shares

YORK, Pa., Aug. 31, 2011 /PRNewswire/ -- Unilife Corporation ("Unilife" or the "Company") (NASDAQ: UNIS; ASX: UNS) today announced that its Chief Operating Officer, Dr. Ramin Mojdeh, will purchase more than $250,000 in shares of the Company's common stock. This investment closely follows Dr. Mojdeh's initial open market purchase of more than $250,000 in Unilife shares in March 2011, six weeks after he joined the Company.

Dr. Mojdeh will begin making the purchase at market prices after the issuance of this release in the U.S.  This intended purchase by Dr. Mojdeh, of more than $250,000 in Unilife common stock is occurring as per the Company's insider trading policy and will be effected in compliance with applicable U.S. and Australian securities laws.

The upcoming purchase by Dr. Mojdeh follows similar activity recently undertaken by Unilife CEO Alan Shortall, as reported on August 17, 2011.  

Dr. Mojdeh stated: "Since joining Unilife nearly seven months ago, my confidence in the Company's future continues to grow. Under Mr. Shortall's guidance and keen leadership, we have been able to accomplish several important milestones including the industrialization and first sales of the Unifill syringe. Through our unparalleled capacity to identify and respond to the unmet needs of our pharmaceutical partners with speed, agility and reliability, we have developed an innovative and highly differentiated portfolio of advanced drug delivery systems.

"Unilife is very well positioned to capitalize on a paradigm shift that is now occurring within the fast-growing $10 Billion market for injectable drug delivery devices. The molecular complexity and patient-centric focus of the biologics now dominating the development pipelines of many pharmaceutical companies requires innovative device solutions that are customized to address the specific needs of each target drug. We now have the diversified portfolio, deep industry expertise and advanced operational capabilities and entrepreneurial structure to serve as a preferred partner to pharmaceutical companies seeking device innovation," concluded Dr. Mojdeh.

About Unilife CorporationUnilife Corporation (NASDAQ: UNIS / ASX: UNS) is a U.S.-based developer, manufacturer and supplier of advanced drug delivery systems with state-of-the-art facilities in Pennsylvania. Established in 2002, Unilife works with pharmaceutical and biotechnology companies seeking innovative devices for use with their parenteral drugs and vaccines. Unilife has developed a broad, differentiated proprietary portfolio of its own injectable drug delivery products, including the Unifill® and Unitract® product lines of safety syringes with automatic, operator controlled needle retraction. Unifill represents the world's first prefilled syringe technology integrating safety within the primary drug container. The products are ideally positioned to help pharmaceutical companies maximize the lifecycle of their injectable drugs and enhance patient care. Unifill syringes, together with other devices that are part of the Unilife technology platform, can either be supplied to pharmaceutical customers ready for use, or customized to address the specific requirements of targeted novel drugs.  For more information on Unilife, please visit

Forward-Looking Statements This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission. 

General: UNIS-G Investor Contacts (US):Investor Contacts (Australia)Todd Fromer / Garth Russell

Stuart Fine

Jeff CarterKCSA Strategic Communications

Carpe DM Inc

Unilife CorporationP: + 1 212-682-6300

P: + 1 908 469 1788

P: + 61 2 8346 6500

SOURCE Unilife Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Unilife Corporation Announces Preliminary Financial Results for the Fourth Quarter and Fiscal Year 2011
2. Unilife Develops Proprietary Range of Auto-Injectors for Patient Self-Administration of Injectable Drugs
3. Unilife Develops Unifill® EZMix Multiple-Chamber Prefilled Syringes
4. Unilife Signs $10 Million Equipment Financing Agreement
5. Unilife Expands Management Team to Support Business Growth
6. Unilife Starts Unifill Syringe Sales to Another Pharmaceutical Customer
7. Unilife Successfully Completes Industrialization of Unifill Syringe
8. Unilife Hosts White House Business Council Meeting
9. Unilife to Present at the 2011 Jefferies Global Healthcare Conference in New York City
10. Unilife to Present at the 2011 UBS Global Specialty Pharmaceuticals Conference in London
11. Unilife Announces Financial Results for the Third Quarter of Fiscal 2011
Post Your Comments:
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
(Date:11/25/2015)...  Today AVACEN Medical announced the issue of United States patent No. ... ". This patent shields the company,s AVACEN 100 dry heat therapy medical device and specific methods ... Photo - ... ... ...
(Date:11/25/2015)... , Nov. 25, 2015 USP 800 ... drug preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, ... technicians). The chapter also covers all entities which ... pharmacies, hospitals, other healthcare institutions, patient treatment clinics, ... --> --> What is ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert ... Organizations, One Beat ” campaign. The partnership between the two groups began in 2014 ... MAP International’s cause. , MAP International was founded in 1954 and is an international ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug rehabilitation ... new cutting edge recovery program that has been 50 years in the making. ... with the purpose to free addicts from the symptoms and negative behaviors of addiction. ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for ... aware of the benefits of Botox® in the treatment of moderate facial wrinkling, few ... and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted by an ... IL, UV Angel is evaluating the efficacy of its product and its disinfection protocol. ... 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic medical ...
(Date:11/25/2015)... Spring, Md (PRWEB) , ... November 25, 2015 ... ... Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible ... history of this disease. The Periwinkle Pioneers, nominated by the public, will receive ...
Breaking Medicine News(10 mins):